New ASH guideline: VTE prophylaxis after major surgery
December 12, 2019
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the American Society of Hematology.
Pulmonary embolism treatment teams adopted widely for complex disease
November 20, 2019
NEW YORK – The challenge of pulmonary embolism is being increasingly addressed with dedicated teams.
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
October 15, 2019
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
Older IBD patients are most at risk of postdischarge VTE
September 10, 2019
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
Rivaroxaban tied to higher GI bleeding than other NOACs
June 17, 2019
SAN DIEGO – Real-world studies comparing the GI bleeding rates among different non–vitamin K anticoagulants have been limited.
Occurrence of pulmonary embolisms in hospitalized patients nearly doubled during 2004-2015
March 24, 2019
NEW ORLEANS – National Inpatient Sample data showed that during 2004-2015 hospitalized U.S. patients with a PE diagnosis jumped by 80%.
Supplementary compression doesn’t improve DVT odds in critically ill
February 20, 2019
SAN DIEGO – The procedure carries few risks, aside from patient discomfort.
COPD linked to higher in-hospital death rates in patients with PAD
January 22, 2019
COPD was an independent predictor of in-hospital death and of pulmonary embolism in PAD patients.
ASH releases new VTE guidelines
November 28, 2018
A panel of the American Society of Hematology released more than 150 recommendations for dealing with venous thromboembolism.
All patients with VTE have a high risk of recurrence
November 20, 2018
Researchers suggest rethinking categorization of patients with incident venous thromboembolism.